Abstract

Shikha Bhalla, Vivek Jain, Pushpendra Kumar Khangar and Rupesh Kumar Jain*

ABSTRACT

The design of oral sustained release DDS depends on various factors such as, physicochemical properties of drug, type of delivery system, disease being treated, and patient condition, and treatment duration, presence of food, gastrointestinal motility, and co-administration of other drugs. Sustained release, sustained action, prolonged action controlled release, extended release, depot release these are the various terms used to identify drug delivery systems that are designed to achieve a prolonged therapeutic effect by continuously releasing medication over a long period of time after administration of a single dose of drug. Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels. The aim of the present study to aim to formulate gastro retentive sustained release tablets and evaluate the function of fenugreek seed mucilage as potential matrix forming agent with Atorvastatin for synergistic effect.